{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:15:36Z","timestamp":1781334936733,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM), characterized by the extracellular deposition of an insoluble amyloid protein in the heart, is one of the main causes of heart failure in elderly patients. In this study, our primary objective was to explore the diverse applications and temporal significance of 1-h and 3-h imaging using <jats:sup>99m<\/jats:sup>Tc-PYP in the context of ATTR-CM. Additionally, we compared tracer kinetics in the heart and bone to comprehensively assess the diagnostic advantages and time-related considerations associated with these two incubation periods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-seven patients at Nagasaki University Hospital who underwent <jats:sup>99m<\/jats:sup>Tc-PYP planar, and SPECT cardiac imaging were classified into two groups (ATTR-CM-positive and -negative groups) based on the American Heart Association statement. Cardiac retention was assessed with both a semiquantitative visual score and a quantitative analysis. To assess bone accumulation, a ROI with an equal volume was drawn on the sternum and calculated as the bone-to-contralateral ratio (B\/CL). We also evaluated correlation between heart-to-contralateral lung (H\/CL) ratio and left ventricular wall thickness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among patients who underwent <jats:sup>99m<\/jats:sup>Tc-PYP imaging, the H\/CL ratio was significantly higher at 1\u00a0h than at 3\u00a0h regardless of the group (from 2.20\u2009\u00b1\u20090.36 to 1.99\u2009\u00b1\u20090.35, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01 in the positive group and from 1.35\u2009\u00b1\u20090.12 to 1.19\u2009\u00b1\u20090.21, <jats:italic>p<\/jats:italic>\u2009=\u20090.01 in the negative group). The gap of H\/CL between highest H\/CL of negative case and lowest H\/CL of positive case was narrower in 3\u00a0h. On the other hand, correlation between H\/CL and left ventricular posterior wall thickness tends to be clearer in 3\u00a0h (<jats:italic>p<\/jats:italic>\u2009=\u20090.12, <jats:italic>r<\/jats:italic>\u2009=\u20090.30 for 1\u00a0h, <jats:italic>p<\/jats:italic>\u2009=\u20090.04, <jats:italic>r<\/jats:italic>\u2009=\u20090.39 at 3\u00a0h).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study suggests that both 1-h and 3-h incubation times for <jats:sup>99m<\/jats:sup>Tc-PYP imaging have different benefits for ATTR cardiac amyloidosis. A one-hour incubation may be preferable for differential diagnostic purposes, while a three-hour incubation may provide greater utility in evaluating disease severity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01629-y","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T07:01:34Z","timestamp":1704524494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing cardiac amyloidosis assessment: utility of 1-h and 3-h 99mTc-PYP imaging"],"prefix":"10.1186","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-3224","authenticated-orcid":false,"given":"Aiganym","family":"Imakhanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ideguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"1","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/hrt.2009.190405","volume":"97","author":"SW Dubrey","year":"2011","unstructured":"Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75\u201384.","journal-title":"Heart"},{"issue":"7","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","volume":"17","author":"A Martinez-Naharro","year":"2020","unstructured":"Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020;17(7):413\u201326.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola I, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232\u20139.","journal-title":"Ann Med"},{"issue":"38","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, De Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585\u201394.","journal-title":"Eur Heart J"},{"issue":"2","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195\u2013201.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-22.","journal-title":"Circulation"},{"issue":"16","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368.","journal-title":"Eur Heart J"},{"issue":"24","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"8","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880\u20139.","journal-title":"JAMA Cardiol"},{"key":"1629_CR10","unstructured":"Dorbala S, Bokhari S, Miller EJ, Bullock-Palmer R, Soman P, Thompson R. 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. ASNC Pract Points. 2016;"},{"issue":"6","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am College Cardiol. 2005;46(6):1076\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073.","journal-title":"J Am College Cardiol."},{"issue":"6","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368\u201383.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s12350-023-03203-9","volume":"30","author":"S Pandey","year":"2023","unstructured":"Pandey S, Teruya S, Rodriguez C, Fine D, Sabogal N, Winburn M, et al. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc 99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis\u202f: the SCAN-MP study. J Nucl Cardiol. 2023;30(4):1414\u20139. https:\/\/doi.org\/10.1007\/s12350-023-03203-9.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"1629_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.010249","volume":"13","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2020;13(2): e010249.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","volume":"15","author":"DF Hutt","year":"2014","unstructured":"Hutt DF, Quigley A-M, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289\u201398.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"1629_CR16","first-page":"1366","volume":"35","author":"K Okuda","year":"1994","unstructured":"Okuda K, Nohara R, Fujita M, Tamaki N, Konishi J, Sasayama S. Technetium-99m-pyrophosphate uptake as an indicator of myocardial injury without infarct. J Nucl Med. 1994;35(8):1366\u201370.","journal-title":"J Nucl Med"},{"issue":"2","key":"1629_CR17","first-page":"284","volume":"38","author":"MB Pepys","year":"1979","unstructured":"Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284\u201393.","journal-title":"Clin Exp Immunol"},{"key":"1629_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","volume":"64","author":"M Papathanasiou","year":"2023","unstructured":"Papathanasiou M, Kessler L, Bengel FM, Jakstaite A, Kersting D, Varasteh Z, et al. Regression of myocardial 99m Tc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis. J Nucl Med. 2023;64:1083\u20136.","journal-title":"J Nucl Med"},{"issue":"9","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1007\/s00380-022-02048-5","volume":"37","author":"MY Henein","year":"2022","unstructured":"Henein MY, Pilebro B, Lindqvist P. Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy. Heart Vessels. 2022;37(9):1562\u20139. https:\/\/doi.org\/10.1007\/s00380-022-02048-5.","journal-title":"Heart Vessels"},{"issue":"5","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11604-021-01221-6","volume":"40","author":"K Ogasawara","year":"2022","unstructured":"Ogasawara K, Shiraishi S, Tsuda N, Sakamoto F, Oda S, Takashio S, et al. Usefulness of quantitative 99mTc-pyrophosphate SPECT\/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis. Jpn J Radiol. 2022;40(5):508\u201317. https:\/\/doi.org\/10.1007\/s11604-021-01221-6.","journal-title":"Jpn J Radiol"},{"issue":"August","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1253\/circj.CJ-19-0255","volume":"83","author":"K Marume","year":"2019","unstructured":"Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, et al. Combination of commonly examined parameters is a useful predictor of positive 99 mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis. Circ J. 2019;83(August):1698\u2013708.","journal-title":"Circ J"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01629-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:08:45Z","timestamp":1704798525000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01629-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01629-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Ethics Committee of Nagasaki University Hospital (no. 20111631). Due to the retrospective nature of the study, written informed consent was waived by the Ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have provided their consent for the manuscript to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}